177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio

Conclusion: With greatly enhanced tumor uptake and tumor-to-kidney absorbed dose ratio, 177Lu-HTK03121 and 177Lu-HTK03123 have the potential to improve treatment efficacy using significantly lower quantities of 177Lu and are promising candidates for clinical translation to treat metastatic castration-resistant prostate cancer.

Source: Journal of Nuclear Medicine - March 29, 2021 Category: Nuclear Medicine Authors: Kuo, H.-T., Lin, K.-S., Zhang, Z., Uribe, C. F., Merkens, H., Zhang, C., Benard, F. Tags: Basic Source Type: research